Altimmune Announces New Data From Phase 2b Trial Of Pemvidutide Showing Improvements Across Multiple Non-Invasive Tests Of Metabolic Dysfunction-Associated Steatoheaptitis Activity And Fibrosis.
HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $20
Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil
Citizens Maintains Market Outperform on Altimmune, Lowers Price Target to $11
Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript
Altimmune Inc (ALT) Q1 2026 Earnings Call Highlights: Strong Cash Position and Strategic ...
Altimmune (ALT) Q1 2026 Earnings Transcript
Altimmune Q1 Earnings Call Highlights
Altimmune Q1 2026 Earnings Call: Complete Transcript
Altimmune shares climb after first-quarter loss beats expectations (ALT)
Altimmune Announces First Quarter 2026 Financial Results and Business Update
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
Altimmune To Present Analyses Of Data From IMPACT Phase 2b Clinical Trial In Metabolic Dysfunction-Associated Steatohepatitis At EASL Congress 2026
Altimmune Q1 EPS $(0.18) Beats $(0.25) Estimate.
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
Altimmune shares are trading lower after the company announced the pricing of its $225 million oversubscribed public offering of 64.25 million shares at $3.00 per share.
Why Is Altimmune Stock Falling Today?
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
